NEWTOWN, Pa., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM) (TSX:HSM.S) (HSM.WT.S) (OTCQB:HSDT) ("Helius" or the "Company") celebrated the company’s expansion into a new, 10,400-square-foot corporate headquarters in Newtown, Penn. The expanded space will house the company’s corporate and clinical teams, as well as a new, state-of-the-art physical rehabilitation clinic. The move supports Helius’ plans to commercialize its novel device, the Portable Neuromodulation Stimulator (PoNS™), in the first half of 2018. The PoNS is currently being investigated in clinical trials for the treatment of chronic balance deficits resulting from mild-to-moderate Traumatic Brain Injury (mTBI).
A photo accompanying this announcement is available at http://heliusmedical.com/images/news_releases/20170814helius001.jpg
“We are delighted with our new headquarters as it allows us to continue to build our clinical and commercialization infrastructure for the PoNS™ Therapy,” said CEO Philippe Deschamps. “The Greater Philadelphia Region is known to be home to a large community of innovative pharma and biotech companies. We look forward to being a part of this community and continuing its tradition of success in the healthcare industry.”
Deschamps highlighted local programs designed to provide resources and the right environment for companies like Helius to grow, including the Advanced Manufacturing for the Medical Device Industry (AMMDI), Life Sciences of Pennsylvania and the emerging Greater Philadelphia MedTech Collaboration.
The grand opening was attended by local dignitaries, investors, and Emmy Award winning television host Montel Williams, who is an original founder of Helius and shareholder.
“Today marks a great day for Helius and I am delighted to be a part of this celebration,” said Montel Williams. “We must continue to work tirelessly to bring about new treatment options for our veterans and all others who have been affected by Traumautic Brain Injury.”
About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of chronic balance deficits for subjects with mild-to-moderate Traumatic Brain Injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. For more information, please visit www.heliusmedical.com.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).
All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the expected use of proceeds from the Private Placement and the business objectives of the Company.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the necessity of conducting successful clinical testing to establish safety and effectiveness of the PoNS Therapy for human performance improvement, the requirement for regulatory approval for marketing for human performance improvement prior to the Company’s ability to commercialize the PoNS Therapy for such indications, and other risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s Transition Report on Form 10-KT for the period ended December 31, 2016, which has been filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com, and the Company’s other filings with the SEC and Canadian securities regulators from time to time.
The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.